A Study in Healthy Men to Test Whether Zongertinib Influences the Amount of 4 Other Medicines (Dabigatran, Rosuvastatin, Metformin, and Furosemide) in the Blood
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Dabigatran-etexilate
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 32
- Registration Number
- NCT06504862
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
A Study to Test How Different Doses of BI 1815368 Are Tolerated and How BI 1815368 is Taken up in the Body of Healthy Japanese Men
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 26
- Registration Number
- NCT06494774
- Locations
- 🇯🇵
SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan
A Study in Healthy Men to Test Whether Zongertinib Affects How 3 Other Medicines (Midazolam, Omeprazole, and Repaglinide) Are Taken up and Processed by the Body
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT06494761
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
A Study in Chinese People With Overweight or Obesity to Test How Different Doses of Survodutide Are Taken up in the Body
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT06492135
- Locations
- 🇨🇳
Shanghai Central Hospital of Xuhui District, Shanghai, China
Real-life-persistence to Antifibrotic Treatments
Active, not recruiting
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 10646
- Registration Number
- NCT06485635
- Locations
- 🇫🇷
Clinityx, Boulogne-Billancourt, France
A Study in Healthy People to Compare Two Different Sifrol® Tablets
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 28
- Registration Number
- NCT06457204
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
A Study in Healthy Men to Test How Well Different Doses of BI 3731579 Are Tolerated
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 64
- Registration Number
- NCT06429137
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
Phase 3
Recruiting
- Conditions
- Heart Failure
- Interventions
- First Posted Date
- 2024-05-22
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 6000
- Registration Number
- NCT06424288
- Locations
- 🇺🇸
Pinnacle Research Group, LLC, Anniston, Alabama, United States
🇺🇸Diagnostic and Medical Clinic, Mobile, Alabama, United States
🇺🇸Mobile Heart Specialists, PC, Mobile, Alabama, United States
A Study in Healthy Men to Test Whether Esomeprazole Influences the Amount of BI 3000202 in the Blood
- First Posted Date
- 2024-05-17
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 15
- Registration Number
- NCT06419660
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
A Study in Healthy People to Test How BI 1015550 is Taken up in the Body When Given With or Without Food
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 18
- Registration Number
- NCT06415045
- Locations
- 🇩🇪
CRS Clinical Research Services Berlin GmbH, Berlin, Germany
© Copyright 2025. All Rights Reserved by MedPath